PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.

about

Hodgkin lymphoma, version 2.2015.PET/CT in Oncology: Current Status and Perspectives.The Impact of 2-(18) Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) in Treatment Strategy of Hodgkin Lymphoma-Current Hematologic Concepts.

P2860

Q30769157-E0619BF6-8293-4509-B4A9-91E9226E8FD0 Q33665109-3D29AFB6-3468-428E-961C-CF72424EFB47 Q37668943-68493681-BCB4-4628-8BE3-E50D8E9398B5

P2860

PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.

Item

http://www.wikidata.org/entity/Q38018865

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

PET/CT adapted therapy in Hodg ...... the art and future directions.

@en

type

Item

label

PET/CT adapted therapy in Hodg ...... the art and future directions.

@en

prefLabel

PET/CT adapted therapy in Hodg ...... the art and future directions.

@en

P1476

PET/CT adapted therapy in Hodg ...... the art and future directions.

@en

P2093

Eldad J Dann

http://www.w3.org/2001/XMLSchema#string

P2860

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.

A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin's lymphoma.

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome.

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

P2888

s11912-012-0250-z

P304

403-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-012-0250-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023003771

http://www.w3.org/2001/XMLSchema#string

P698

22700011

http://www.w3.org/2001/XMLSchema#string

PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.

about

P2860

P2860

PET/CT adapted therapy in Hodgkin disease: current state of the art and future directions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698